Table 3.
Univariate analysis for GS upgrading and disease upstaging
| GS upgrading | Disease upstaging | |||||
|---|---|---|---|---|---|---|
|
| ||||||
| Variables | OR | 95% CI | p value | OR | 95% CI | p value |
| Age | 1.066 | 0.645–1.316 | 0.844 | 1.010 | 0.326–1.174 | 0.997 |
| PSA | 1.534 | 1.078–2.544 | 0.008 | 1.045 | 0.555–1.872 | 0.851 |
| Two positive cores vs. one positive core | 1.399 | 0.680–3,102 | 0.428 | 1.148 | 0.677–1.842 | 0.812 |
| Maximum percentage of cancer in a core | 1.147 | 0.792–2.889 | 0.814 | 1.209 | 0.804–2.114 | 0.572 |
| Clinical stage (cT2a vs. cT1c) | 1.115 | 0.398–2.012 | 0.838 | 1.015 | 0.417–1.887 | 0.894 |
| NLR ≥2.5 | 2.234 | 1.131–5.712 | 0.003 | 1.122 | 0.571–1.874 | 0.667 |
| NC ≥4.2 × 1019/L | 1.266 | 0.603–2.655 | 0.781 | 1.117 | 0.566–1.767 | 0.821 |
| LC ≥1.4 × 1019/L | 1.205 | 0.497–2.667 | 0.821 | 1.085 | 0.381–1.884 | 0.965 |
CI: confidence interval; GS: Gleason score; LC: lymphocyte count; neutrophil count; NLR: neutrophil-to-lymphocyte ratio; OD: odds ratio; PSA: prostate-specific antigen.